OOIR: Observatory of International Research

Papers

(The TQCC of Trends in Pharmacological Sciences is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Subscription and Copyright Information	644
Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease	424
Subscription and Copyright Information	252
Subscription and Copyright Information	178
Subscription and Copyright Information	163
Advisory Board and Contents	157
Structural asymmetry in FGF23 signaling	153
Subscription and Copyright Information	142
DOT1L: orchestrating methylation-dependent radiotheRAPy responses via BRCA1	140
Targeting of Potassium Channels in Cardiac Arrhythmias	131
Assembling the P450 puzzle: on the sources of nonadditivity in drug metabolism	131
Structural pharmacology and mechanisms of GLP-1R signaling	120
Muscarinic receptors: from clinic to bench to clinic	106
Advancing chemical carcinogenicity prediction modeling: opportunities and challenges	104
Shearing of surface mucin saps tumor cell strength	104
Direct in vivo CAR T cell engineering	92
Peptides as a therapeutic strategy against Klebsiella pneumoniae	90
Compstatins: the dawn of clinical C3-targeted complement inhibition	88
Targeting complement in neurodegeneration: challenges, risks, and strategies	88
Therapeutic inhibition of ferroptosis in neurodegenerative disease	80
Advisory Board and Contents	79
Advisory Board and Contents	78
Mechanistic considerations for adenosine-lidocaine-magnesium (ALM) in controlling coagulopathy	78
Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors	77
Phenotypic approaches for CNS drugs	71

Emerging strategies for beta cell transplantation to treat diabetes	68
A smart hospital-driven approach to precision pharmacovigilance	65
Ribosome-directed cancer therapies: the tip of the iceberg?	62
HSV-1 as a gene delivery platform for cancer gene therapy	61
Advisory Board and Contents	60
Liquid–liquid phase separation: a principal organizer of the cell’s biochemical activity architecture	60
A deep dive into degrader-induced protein-protein interfaces	59
A perspective on psychedelic teratogenicity: the utility of zebrafish models	57
Engineering ACE2 decoy receptors to combat viral escapability	56
Advisory Board and Contents	56
siRNA drug Leqvio (inclisiran) to lower cholesterol	56
Leveraging human microbiomes for disease prediction and treatment	56
Genetically engineered loaded extracellular vesicles for drug delivery	56
Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease	56
Mentoring future science leaders to thrive	54
Could dexmedetomidine be repurposed as a glymphatic enhancer?	52
Therapeutic Potential of Targeting Plasminogen Activator Inhibitor-1 in COVID-19	51
The structure, function, and pharmacology of MRGPRs	50
Subscription and Copyright Information	50
Close to a year in TIPS’ saddle – I am optimistic	50
Thriving as members of under-represented groups in pharmacology-related careers	49
Emerging approaches to induce immune tolerance to therapeutic proteins	49
Lipoxygenases in chronic liver diseases: current insights and future perspectives	48
Alzheimer’s therapeutic development: shifting neurodegeneration to neuroregeneration	47
GPR35, ally of the anti-ischemic ATPIF1-ATP synthase interaction	47
Suzetrigine for moderate to severe acute pain	47
Advancing non-destructive analysis of 3D printed medicines	46
Targeting AMPK as a potential treatment for hepatic fibrosis in MASLD	45
The promise of targeted protein degradation approaches	44
Advisory Board and Contents	44
The road less traveled: activating an oncogenic kinase	44
Building unconventional G protein-coupled receptors, one block at a time	43
Salt-inducible kinases: new players in pulmonary arterial hypertension?	43
Hepatic mitochondrial reductive stress in the pathogenesis and treatment of steatotic liver disease	42
Fragment-based drug design facilitates selective kinase inhibitor discovery	42
Targeting the TGF-β signaling pathway for resolution of pulmonary arterial hypertension	41
Mavacamten improves symptoms in obstructive hypertrophic cardiomyopathy patients	41
Inhalable neutralizing antibodies – promising approach to combating respiratory viral infections	40
Subscription and Copyright Information	39
Advisory Board and Contents	39
Promising neuroimmune targets and drugs for CNS diseases	39
A novel function of the M2 muscarinic receptor	39
The end of the beginning in understanding SLC22 polyspecificity	38
Validation of agent-based models of surface receptor oligomerisation	37
Nanocarriers for oral delivery of biologics: small carriers for big payloads	37
BTK inhibitors: past, present, and future	34
Frizzleds act as dynamic pharmacological entities	34
Monkeypox: potential vaccine development strategies	33
Eflornithine for treatment of high-risk neuroblastoma	33
Targeting intracellular protein–protein interactions with macrocyclic peptides	33

Advisory Board and Contents	33
Decoding pseudouridine: an emerging target for therapeutic development	33
Recent advances in generative biology for biotherapeutic discovery	32
Demographic diversity in platelet function and response to antiplatelet therapy	31
Metabolic regulation in normal and leukemic stem cells	31
Engineered antibody fusion proteins for targeted disease therapy	31
Voltage-gated ion channels in epilepsies: circuit dysfunctions and treatments	31
SEAKER cells coordinate cellular immunotherapy with localized chemotherapy	31
GPR35: from enigma to therapeutic target	29
Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches	29
Neurofilament light chain as a biomarker of chemotherapy-induced peripheral neuropathy	28
Circulating tumor cells in precision medicine: challenges and opportunities	28
Development of PROTACs using computational approaches	27
Histone lysine acetyltransferase inhibitors: an emerging class of drugs for cancer therapy	27
Subscription and Copyright Information	27
Subscription and Copyright Information	26
Subscription and Copyright Information	25
Magnesium for disease treatment and prevention: emerging mechanisms and opportunities	25
Oteseconazole (VIVOJA) for prevention of recurrent vulvovaginal candidiasis	24
Biochemical perspectives on targeting KMT2 methyltransferases in cancer	24
Intra- and intercellular signaling pathways associated with drug-induced cardiac pathophysiology	24
A novel anticancer pharmacological agent targeting mitochondrial complex I	24
Harnessing associative learning paradigms to optimize drug treatment	24
Tackling chronic kidney disease in diabetic patients with finerenone	24
Subscription and Copyright Information	24
Biologics and cardiac disease: challenges and opportunities	23
Commemorating insulin's centennial: engineering insulin pharmacology towards physiology	23
Boosting CAR-T cell therapy through vaccine synergy	23
Visceral obesity and HFpEF: targets and therapeutic opportunities	23
Targeting sensory neuron GPCRs for peripheral neuropathic pain	23
Modulation of Wnt–β-catenin signaling with antibodies: therapeutic opportunities and challenges	23
High-power screening (HPS) empowered by DNA-encoded libraries	22
Taming PRMT5–adaptor protein interactions	22
Neutrophil extracellular traps in wound healing	22
Teaching an old dog new tricks: repurposing β-lactams	22
Subscription and Copyright Information	22
Recent advancements in vaccine research and development	22
Crosstalk between androgen receptor and protein kinase G signaling in bone: implications for osteoporosis therapy	22
Targeting methionine aminopeptidase 2 in cancer, obesity, and autoimmunity	21
Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics	21
Potential for targeting small heat shock protein modifications	21
Circadian biology to advance therapeutics for mood disorders	21
NLRP3 and pyroptosis blockers for treating inflammatory diseases	21
GABAA receptors as targets for treating affective and cognitive symptoms of depression	21
Challenges and opportunities associated with rare-variant pharmacogenomics	21
Partial agonists go molecular	21
The structure and function of YTHDF epitranscriptomic m6A readers	20
Advisory Board and Contents	20
Harnessing UBR5 for targeted protein degradation of key transcriptional regulators	20
Targeted protein degrader development for cancer: advances, challenges, and opportunities	19
Glymphatic-stagnated edema induced by traumatic brain injury	19
GPCR-dependent and -independent arrestin signaling	19
Microfluidic technologies for drug discovery and development: friend or foe?	18
Odorant receptors as potential drug targets	18
Membrane protein production and formulation for drug discovery	18
The Importance of Apparent pKa in the Development of Nanoparticles Encapsulating siRNA and mRNA	18
Hans Jürg Schatzmann (1924–2021)	17
Bridging the gap in neuropsychiatric translational research	17
Advisory Board and Contents	17
Malolactone strikes: K-Ras-G12D's Achilles' heel	17
Advisory Board and Contents	17
Learning from natural design for local anesthetic delivery	17